2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Head and Neck Neoplasms
2604
Squamous Cell Carcinoma of Head and Neck
1880
Thyroid Neoplasms
705
Nasopharyngeal Carcinoma
627
Carcinoma, Non-Small-Cell Lung
478
Mouth Neoplasms
424
Breast Neoplasms
383
Neoplasms
381
Oropharyngeal Neoplasms
359
Melanoma
339
Lung Neoplasms
319
Colorectal Neoplasms
307
Carcinoma, Squamous Cell
283
Neoplasm Metastasis
255
Ovarian Neoplasms
254
Laryngeal Neoplasms
253
Salivary Gland Neoplasms
236
Uterine Cervical Neoplasms
234
Stomach Neoplasms
223
Esophageal Neoplasms
222
Nasopharyngeal Neoplasms
221
Pancreatic Neoplasms
213
Prostatic Neoplasms
203
Carcinoma, Renal Cell
201
Thyroid Nodule
179
Thyroid Cancer, Papillary
178
Urinary Bladder Neoplasms
163
Sarcoma
160
Recurrence
143
Hypopharyngeal Neoplasms
143
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
Head & Neck
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled